As the ADC landscape expands, how is datopotamab deruxtecan redefining the treatment paradigm for both breast and lung cancer?

In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Lukas Delasos break down the clinical integration of next-generation ADCs. The discussion differentiates the roles of ADCs such as datopotamab deruxtecan and trastuzumab deruxtecan, examining their impact across HER2-directed and Trop-2 targeted settings in both metastatic breast cancer and thoracic oncology.

Beyond the data, the clinicians share practical insights on navigating sequencing challenges, resistance mechanisms, and the evolving role of biomarkers in personalizing care. A major focus is placed on proactive toxicity management, highlighting essential protocols to ensure treatment continuity and optimize patient outcomes.

A strategic resource for oncology clinicians navigating the future of ADC therapy, biomarker-guided treatment selection, and precision oncology across breast and lung cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #LungCancer #NSCLC #ADC #AntibodyDrugConjugates #HER2Low #EGFR #DatopotamabDeruxtecan #TrastuzumabDeruxtecan #PrecisionOncology #TargetedTherapy #MedicalOncology #ThoracicOncology #BreastOncology #ILD #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM Conversations, Dr. Ruta Rao and Dr. Azadeh Nasrazadani discuss how the detection of PIK3CA, AKT, and PTEN mutations is redefining the role of capivasertib.

The clinicians differentiate the clinical application of capivasertib from other targeted agents like alpelisib and inavolisib, exploring how mechanistic differences and biomarker profiles influence patient selection. A central focus is placed on mastering the safety profile of these agents, providing practical strategies for managing stomatitis, diarrhea, and hyperglycemia to ensure treatment continuity and optimize patient outcomes.

An essential resource for oncology teams navigating the complexities of the PI3K/AKT/PTEN pathway and optimizing supportive care in the second-line metastatic breast cancer landscape.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HRPositive #MetastaticBreastCancer #PrecisionOncology #BiomarkerTesting #PIK3CA #ESR1 #Capivasertib #LiquidBiopsy #EndocrineTherapy #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How is Dato-DXd redefining first-line mTNBC? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the TROPION-Breast02 trial results and how this data fits into the broader landscape alongside the ASCENT-03 findings.

The clinicians focus on the shift toward frontline Trop2-directed strategies and how these agents are challenging the chemotherapy-only paradigm. They also address the practicalities of management—specifically managing stomatitis and ocular toxicity while navigating CNS disease and supportive care.

An essential resource for oncology clinicians navigating the future of precision ADC therapy in triple-negative breast cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#TripleNegativeBreastCancer #TNBC #MetastaticBreastCancer #ADCtherapy #SacituzumabGovitecan #DatopotamabDeruxtecan #Trop2 #BreastOncology #MedicalOncology #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media